National Ventilator Registry Launched by Phunware

“As the United States braces for an onslaught of coronavirus cases, hospitals and governments are confronting a grim reality – there are not nearly enough lifesaving ventilator machines to go around and there is no way to solve the problem before the disease reaches full throttle,” according to a recent NY Times article.

The Johns Hopkins Center for Health Security (JHCHS) estimates that there are about 160,000 ventilators available for patient care, but the American Hospital Association (AHA) estimates 960,000 people may need them over the course of the COVID-19 pandemic. While manufacturers race to ramp production, hospitals and patients need access to real-time utilization data of the existing ventilators in operation.

Phunware’s Knowledge Graph is uniquely suited to track critical data attributes in near real-time, while Phunware’s mobile digital front door provides clinicians with everything they need to monitor and track the utilization of key resources like ventilators. However, to do this across the country, Phunware is calling on the medical community to compile a National Ventilator Registry so that clinicians can have complete visibility on existing resources and patients can locate the lifesaving equipment that they need.

“We have built a data engine that is capable of managing over a billion active devices and four billion daily transactions while generating more than 5 terabytes of data each day,” said Randall Crowder, COO of Phunware. “We can leverage our technology to identify and track critical medical assets like ventilators, but we need to act now and we need everyone’s help getting the word out to medical professionals on the frontline so that we can collect the information that we desperately need.”

More about Phunware’s efforts to locate and track ventilators across the United States in order to optimize resource allocation and utilization visit here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”